A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

NCT05044195 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2044

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza, Human

Interventions

BIOLOGICAL: aQIV
BIOLOGICAL: Comparator QIV

Sponsor

Seqirus